Zinc Effect on Inflammation and Cardiovascular Risk in HIV

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the effect of short-term zinc supplementation on improving inflammation, metabolic, and cardiovascular risk among HIV infected patients on stable anti-retroviral therapy

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospitals Cleveland Medical Center
• Collaborator: Case Western Reserve University

Criteria

Inclusion Criteria:

• HIV-1 infection

• Documentation of an HIV-1 RNA level of ≤400 copies/mL in the last 4 months prior to study entry

• Male or Female age ≥18 years

• Zinc level ≤0.75 mg/L in the last 60 days

Exclusion Criteria:

• Pregnancy/lactation

• Known cardiovascular disease

• Uncontrolled diabetes